Compare Stocks → Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BGXXNASDAQ:BTMDNASDAQ:CDXC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGXXBright Green$0.24-3.9%$0.23$0.15▼$1.81$44.79M0.72.05 million shs853,980 shsBTMDbiote$5.80-1.2%$5.07$3.65▼$8.22$432.27M0.88112,001 shs170,935 shsCDXCChromaDex$3.48-5.2%$1.94$1.25▼$4.06$262.08M1.87223,245 shs486,415 shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGXXBright Green-5.18%-16.00%+20.47%-26.20%-74.63%BTMDbiote-1.19%-7.35%-7.20%+17.41%+8.41%CDXCChromaDex-5.18%+8.75%+101.16%+143.36%+118.87%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBGXXBright GreenN/AN/AN/AN/AN/AN/AN/AN/ABTMDbiote2.3642 of 5 stars3.52.00.00.01.80.81.9CDXCChromaDex4.3197 of 5 stars3.53.00.04.04.00.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGXXBright GreenN/AN/AN/AN/ABTMDbiote3.00Buy$8.1139.83% UpsideCDXCChromaDex3.00Buy$5.8066.67% UpsideCurrent Analyst RatingsLatest BTMD, BGXX, and CDXC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2024BTMDbioteRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $9.002/20/2024BTMDbioteB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.002/1/2024BTMDbioteJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.551/18/2024BTMDbioteTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $9.001/18/2024BTMDbioteRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGXXBright GreenN/AN/AN/AN/A$0.07 per shareN/ABTMDbiote$185.36M2.33$0.49 per share11.85($0.58) per share-10.00CDXCChromaDex$83.57M3.14N/AN/A$0.38 per share9.16Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGXXBright Green-$27.66M-$0.06N/A∞N/AN/A-73.26%-39.82%4/16/2024 (Estimated)BTMDbiote$3.32M-$0.22N/A10.00N/A1.79%-45.10%19.61%5/14/2024 (Estimated)CDXCChromaDex-$4.94M-$0.07N/A58.00N/A-5.91%-17.81%-9.17%5/8/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBGXXBright GreenN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/ACDXCChromaDexN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGXXBright GreenN/A0.030.03BTMDbioteN/A5.514.73CDXCChromaDexN/A2.401.70OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGXXBright Green7.83%BTMDbiote21.68%CDXCChromaDex15.41%Insider OwnershipCompanyInsider OwnershipBGXXBright Green51.38%BTMDbiote16.60%CDXCChromaDex10.57%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBGXXBright Green23183.88 million89.40 millionOptionableBTMDbiote19474.53 million62.16 millionNot OptionableCDXCChromaDex10675.31 million67.35 millionOptionableBTMD, BGXX, and CDXC HeadlinesSourceHeadline3 Chemical Stocks Poised for Gainsstocknews.com - March 27 at 5:01 PMChromaDex (NASDAQ:CDXC) Shares Cross Above 200-Day Moving Average of $1.57americanbankingnews.com - March 27 at 3:44 AMChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Programbusinesswire.com - March 26 at 8:32 AMShort Interest in ChromaDex Co. (NASDAQ:CDXC) Declines By 9.0%marketbeat.com - March 19 at 3:32 PMEquities Analysts Offer Predictions for ChromaDex Co.'s FY2025 Earnings (NASDAQ:CDXC)marketbeat.com - March 14 at 7:36 AMChromaDex Full Year 2023 Earnings: EPS Beats Expectationsfinance.yahoo.com - March 8 at 8:50 AMChromaDex Co. Forecasted to Earn Q1 2025 Earnings of $0.01 Per Share (NASDAQ:CDXC)marketbeat.com - March 8 at 7:22 AMPersona 3 Reload is getting the DLC it needs, but not the one it deservesuk.sports.yahoo.com - March 8 at 1:24 AMChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 7 at 3:23 PMChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDAfinance.yahoo.com - March 7 at 3:23 PMWhat Wall Street expects from ChromaDex's earningsmarkets.businessinsider.com - March 6 at 11:44 PMCDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023investorplace.com - March 6 at 11:01 PMEarnings Preview For ChromaDexbenzinga.com - March 6 at 6:44 PMChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Resultsfinance.yahoo.com - March 6 at 6:44 PMInsiders own 26% of ChromaDex Corporation (NASDAQ:CDXC) shares but retail investors control 44% of the companyfinance.yahoo.com - March 2 at 12:51 PMChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024finance.yahoo.com - February 21 at 12:29 PMChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024businesswire.com - February 21 at 8:32 AMTop 3 Accelerating Chemical Stocks to Considerentrepreneur.com - February 6 at 10:27 AMChromaDex agrees with FDA on NMN decisionnaturalproductsinsider.com - February 5 at 6:35 PMChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024finance.yahoo.com - February 5 at 1:35 PMChromaDex to Present at the Lytham Partners 2024 Investor Select Conferencefinance.yahoo.com - January 26 at 6:46 PMChromaDex: Growth At A Reasonable Priceseekingalpha.com - January 24 at 4:54 PMChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profitfinance.yahoo.com - January 19 at 9:29 AMUnderstanding the Risks of Investing in Chromadex Corp (CDXC)knoxdaily.com - January 1 at 6:04 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBright GreenNASDAQ:BGXXBright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.bioteNASDAQ:BTMDbiote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.ChromaDexNASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.